<DOC>
	<DOCNO>NCT02584699</DOCNO>
	<brief_summary>This study aim prospectively investigate efficacy , toxicity quality life ( QOF ) stereotactic ablative radiotherapy ( SABR ) use moderate fractionation 72 Gy/6 Gy/12 F ( BED10 = 115 Gy ) single arm elderly ( ≥ 70 ) patient stage I ( 2009 UICC ) non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study Stereotactic Ablative Radiotherapy ( SABR ) Elderly Stage I NSCLC</brief_title>
	<detailed_description>This study aim prospectively investigate local regional control , overall survival , treatment related toxicity quality life ( QOF ) elderly stage I NSCLC patient receive stereotactic ablative radiotherapy ( SABR ) moderate fractionation 72 Gy/6 Gy/12 F ( BED10 = 115 Gy ) . Patients ' general characteristic , treatment modality , dose-volume histogram ( DVH ) parameter , toxicity profiling , quality life , pattern failure well survival time prospective record analysis .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Age ≥ 70 Pathologically cytologically confirm NSCLC Stage T1 2 N0M0 base adequate workup Peripheral tumor Eastern Cooperative Oncology Group ( ECOG ) 01 Inoperable NSCLC Pathologically cytologically confirm SCLC Direct evidence regional distant metastasis Central tumor Past history malignancy Past history thoracic irradiation Past history chemotherapy Past history thoracic surgery Pure Bronchioalveolar adenocarcinoma Active systemic , pulmonary pleural lung disease Pulmonary infection</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>